Literature DB >> 2162238

Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice.

M J Silverstein1, J R Waisman, P Gamagami, E D Gierson, W J Colburn, R J Rosser, P S Gordon, B S Lewinsky, A Fingerhut.   

Abstract

Two hundred eight cases of intraductal breast carcinoma (DCIS) were selectively treated; 97 with mastectomy, 96 with radiation therapy, and 15 using excisional biopsy only. Mastectomy patients tended to have larger tumors, involved biopsy margins, palpable and often multifocal tumors. Breast preservation patients tended to have smaller, often occult, tumors with clear surgical margins. Before 1983, mastectomy was more common; during and after 1983, breast preservation was more common. Comedocarcinomas were the most frequent tumors. They were the largest, had the highest percentage of microinvasion (20%), and had the highest recurrence rate (8%). Noncomedo DCIS had a recurrence rate of 1%, one of 103 tumors. The recurrence rate for comedocarcinomas treated with radiation therapy was nearly three times higher than for those treated with mastectomy (11% versus 4%). One of 164 (0.6%) axillary lymph node dissections yielded positive nodes. Nine patients have recurred: two in the mastectomy group and seven in the breast conservation group (P less than 0.1). Eight of nine recurrences were the comedo subtype (P less than 0.05). Three patients developed metastatic disease, two of whom have died. Axillary dissection for intraductal carcinoma of the breast is unlikely to yield involved nodes and is not indicated for most cases. It should be reserved for lesions revealing microinvasion. Conservative therapy for comedocarcinoma must be viewed with caution.

Entities:  

Mesh:

Year:  1990        PMID: 2162238     DOI: 10.1002/1097-0142(19900701)66:1<102::aid-cncr2820660119>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Ductal Carcinoma In Situ of the Breast: Is Breast Conserving Treatment Feasible?

Authors: 
Journal:  Breast Cancer       Date:  1996-06-28       Impact factor: 4.239

2.  [Prognostic factors in ductal carcinoma in situ].

Authors:  A Lebeau
Journal:  Pathologe       Date:  2006-09       Impact factor: 1.011

3.  Prospective comparison of stereotactic core biopsy and surgical excision as diagnostic procedures for breast cancer patients.

Authors:  M Morrow; L Venta; T Stinson; C Bennett
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

4.  Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013.

Authors:  Alexandra Thomas; Ronald J Weigel; Charles F Lynch; Philip M Spanheimer; Elizabeth K Breitbach; Mary C Schroeder
Journal:  Am J Surg       Date:  2016-09-02       Impact factor: 2.565

5.  Determining factors which predict response to primary medical therapy in breast cancer using a single fine needle aspirate with immunocytochemical staining and flow cytometry.

Authors:  I N Fernando; T J Powles; M Dowsett; S Ashley; L McRobert; J Titley; M G Ormerod; N Sacks; M C Nicolson; A Nash
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

Review 6.  Management of in situ and minimally invasive breast carcinoma.

Authors:  E R Frykberg; K I Bland
Journal:  World J Surg       Date:  1994 Jan-Feb       Impact factor: 3.352

Review 7.  [Is axillary dissection in clinically lymph node-negative breast carcinoma further indicated?].

Authors:  F K Böhler; H Eiter; W Rhomberg
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

8.  Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

Authors:  J D Iglehart; B J Kerns; G Huper; J R Marks
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

Review 9.  Microinvasive carcinoma of the breast.

Authors:  Simonetta Bianchi; Vania Vezzosi
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

Review 10.  The need for epidemiologic studies of in-situ carcinoma of the breast.

Authors:  R Millikan; L Dressler; J Geradts; M Graham
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.